消化

订阅

MedSci主页 / 所有栏目 / 消化

CSMO 2014 ：David Kerr教授谈结直肠癌氟尿嘧啶化疗的敏感性标志物

2014-07-07 贾春实 报道 中国医学论坛报

结直肠癌化疗
关注

欧洲肿瘤内科学会前任主席、英国牛津大学的David Kerr教授 在7月（3日）的第八届中国肿瘤内科大会开幕式上，David Kerr教授向参会专家就结直肠癌">结直肠癌化疗敏感性生物学标志物鉴定方面的研究进行了介绍。 Kerr教授讲到，目前，我们需要建立较大的生物标志物数据库，这样才能有足够的统计学分析能力来建设来鉴定具有预测功能的生物学标志物。随机临床试验，组织标

欧洲肿瘤内科学会前任主席、英国牛津大学的David Kerr教授

在7月（3日）的第八届中国肿瘤内科大会开幕式上，David Kerr教授向参会专家就结直肠癌">结直肠癌化疗敏感性生物学标志物鉴定方面的研究进行了介绍。

Kerr教授讲到，目前，我们需要建立较大的生物标志物数据库，这样才能有足够的统计学分析能力来建设来鉴定具有预测功能的生物学标志物。随机临床试验，组织标本与高质量研究数据能够提供理想的证实药物特异性的诊断方法。

实时定量PCR(RT-PCR)检测对于明确5-Fu化疗敏感性的基因组特征意义不大。以癌症功能为基础的shRNA筛查研究发现了对5-Fu化疗敏感性意义重大的生物学标志物。

这些生物标志物正在1800例肿瘤组织标本中进行检测(QUASAR1临床试验)。未来，对于奥沙利铂以及伊立替康药物敏感性，都会应用该方法对其敏感性进行研究。


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703574, encodeId=3f111e03574e1, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Feb 20 10:06:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840813, encodeId=8800184081346, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon May 11 22:06:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024684, encodeId=528d202468421, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jun 02 10:06:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388306, encodeId=3c271388306fa, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452703, encodeId=c69f1452e032f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542843, encodeId=3390154284365, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
    2015-02-20 surilei

    #ERR#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1703574, encodeId=3f111e03574e1, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Feb 20 10:06:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840813, encodeId=8800184081346, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon May 11 22:06:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024684, encodeId=528d202468421, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jun 02 10:06:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388306, encodeId=3c271388306fa, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452703, encodeId=c69f1452e032f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542843, encodeId=3390154284365, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
    2015-05-11 hukaixun

    #标志物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1703574, encodeId=3f111e03574e1, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Feb 20 10:06:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840813, encodeId=8800184081346, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon May 11 22:06:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024684, encodeId=528d202468421, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jun 02 10:06:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388306, encodeId=3c271388306fa, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452703, encodeId=c69f1452e032f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542843, encodeId=3390154284365, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
    2015-06-02 liuhuangbo

    #SMO#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1703574, encodeId=3f111e03574e1, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Feb 20 10:06:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840813, encodeId=8800184081346, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon May 11 22:06:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024684, encodeId=528d202468421, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jun 02 10:06:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388306, encodeId=3c271388306fa, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452703, encodeId=c69f1452e032f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542843, encodeId=3390154284365, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
    2014-07-09 ms5236388012055669

    #敏感性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1703574, encodeId=3f111e03574e1, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Feb 20 10:06:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840813, encodeId=8800184081346, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon May 11 22:06:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024684, encodeId=528d202468421, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jun 02 10:06:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388306, encodeId=3c271388306fa, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452703, encodeId=c69f1452e032f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542843, encodeId=3390154284365, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
    2014-07-09 crystal0564

    #结直肠#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1703574, encodeId=3f111e03574e1, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Feb 20 10:06:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840813, encodeId=8800184081346, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon May 11 22:06:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024684, encodeId=528d202468421, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jun 02 10:06:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388306, encodeId=3c271388306fa, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452703, encodeId=c69f1452e032f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542843, encodeId=3390154284365, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Jul 09 02:06:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
    2014-07-09 12498710m15暂无昵称

    #氟尿嘧啶#

    0

相关资讯

Anticancer Res：S-1、伊立替康联合贝伐单抗治疗转移性结直肠癌患者的II期试验

背景：伊立替康可引起S期特异性细胞死亡，其活性代谢物SN-38是由羧酸酯酶催化的。长时间暴露于低浓度的伊立替康与饱和的羧酸酯酶，可增强治疗效果（Houghton PJ，1995，Rothenberg ML，1998）。曾报道过口服UFT/亚叶酸钙或S-1联合24小时输注伊立替康是非常有效的。因此对S-1、24小时输注伊立替康联合贝伐单抗治疗转移性结直肠癌（mCRC）的有效性和安全性进行了研究。

Gastroenterology：结直肠癌中miR-221/222介导NFκB和STAT3通路激活

国际胃肠病学权威期刊Gastroenterology在线发表了中科院上海生命科学研究院/上海交通大学医学院健康科学研究所张笑人研究组的最新研究成果，揭示miR-221/22介导的炎症信号正反馈环路在结直肠癌发生和发展过程中的重要作用。结直肠癌是胃肠道系统中最常见的恶性肿瘤之一，其发病率居恶性肿瘤第三位，患者死亡率高居恶性肿瘤死因第二位。近年来，我国结直肠癌的发病率和死亡率呈明显上升趋势。越来越多的

CSCRS 2014：达芬奇机器人手术系统造福结直肠癌患者

达芬奇机器人手术系统行结直肠癌">结直肠癌根治术在许多国家和地区已经得以开展。与传统腹腔镜手术相比，达芬奇机器人手术系统具有一个显著的优势，即在狭小的空间中可以获得灵活的操作和清晰的视野。达芬奇机器人手术系统的眼手同向协调和三维高清视野，使其具有接近于开腹手术的直观效果，故学习曲线短，特别适合没有腹腔镜基础的外科医生。从手术效果而言，达芬奇机器人手术系统的安全性与可行性得到了全面的肯定，术后

S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究)

背景：SOFT研究已表明SOX联合贝伐珠单抗（SOX+ BEV）的无进展生存期（PFS，主要研究终点）非劣效于mFOLFOX6联合贝伐珠单抗（mFOLFOX6+BEV）（Yamada Y, et al. 《柳叶刀肿瘤学》2013月，14（13）：1278-86）。本次报告中位随访3年以上的总生存期（OS）最终结果。 方法：SOFT研究是对ECOG PS评分为0-1、器官功能完善、初治的转移性结直

Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果

背景：一项对比卡培他滨联合奥沙利铂（COX）与S-1联合奥沙利铂（SOX）一线治疗转移性结直肠癌">结直肠癌试验的无进展生存期（PFS）和总生存期（OS）的最新数据报告。 方法：一项对比COX与SOX的随机双臂非劣效性的III期研究，COX：第1至14天每日两次给予卡培他滨1000 mg/m2、第1天给予奥沙利铂130 mg/m2；SOX：第1至14天每日给予S-1 80-120mg/天、

CSCRS 2014：结合肿瘤生物学行为，形成三维思维模式

肿瘤传统分期仍局限于线性思维 肿瘤治疗无外乎预防、早期诊断和合理治疗，对于肿瘤细致的分期、分级、分型，最终帮助指导临床治疗，提高患者的生存率。 无论是1932年提出的Dukes结直肠癌">结直肠癌分期标准，1955年美国癌症联合委员会（AJCC）癌症分期手册对结直肠癌的分期，还是沿用至今2010年第7版的TNM分期标准，肿瘤传统分期仍局限于线性思维的模式，没有将肿瘤的生物学特性融合其中。